Follow Expert Insight, Commentary, and Intelligence On...

Latest Updates

AI Reporter - July 2025

Much of the AI conversation in June focused on the Trump Administration’s “Big Beautiful Bill” and its proposed 10-year moratorium on state AI regulation. The provision received major pushback in both the Senate and several state… more

What’s Up With WOTUS?

The intricacies of the Waters of the U.S. (WOTUS) definition continue to evolve, especially with recent changes initiated under the Trump administration and landmark clarifications from the Supreme Court's Sackett v. EPA decision… more

District of Columbia TOPA Reform Alert

When District of Columbia Council Chairman Phil Mendelson introduced the Rebalancing Expectations for Neighbors, Tenants and Landlords (RENTAL) Act, there were high hopes that much needed reform to the Tenant Opportunity to Purchase… more

Spotlight On: Humira® (adalimumab) / Amjevita™ (adalimumab-atto) / Cyltezo® (adalimumab-adbm) / Hyrimoz™ (adalimumab-adaz) / Hadlima™ (adalimumab-bwwd) / Abrilada™ (adalimumab-afzb) / Hulio® (adalimumab-fkjp) / Yusimry™ (adalimumab-aqvh) / Idacio® (adalimumab-aacf) / Yuflyma® (adalimumab-aaty) / Simlandi® (adalimumab-ryvk) - July 2025

Adalimumab Challenged Claim Types in IPR and Litigation: Claims include those challenged in litigations and IPRs. Claims are counted in each litigation and IPR, so claims from the same patent challenged in multiple litigations/IPRs are… more

Federal Circuit Review | June 2025

In Dolby Laboratories Licensing Corporation V. Unified Patents, LLC, Appeal No. 23-2110, the Federal Circuit held that a patent owner lacks Article III standing to appeal an inter partes review decision on patentability when it cannot… more

Watch This